0001415889-24-015552.txt : 20240605
0001415889-24-015552.hdr.sgml : 20240605
20240605161149
ACCESSION NUMBER: 0001415889-24-015552
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240603
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 241022125
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811173868
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-314-6297
MAIL ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
form4-06052024_080645.xml
X0508
4
2024-06-03
0001664710
Keros Therapeutics, Inc.
KROS
0001221590
BIENAIME JEAN JACQUES
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
LEXINGTON
MA
02421
true
false
false
false
0
Stock Option (right to buy)
48.67
2024-06-03
4
A
0
17600
0
A
2034-06-02
Common Stock
17600
17600
D
One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on September 3, 2024, subject to the Reporting Person continuing to provide service through each such date.
/s/ Keith Regnante, Attorney-in-Fact
2024-06-05